FDC Limited Receives FDA Approval for Generic Pilocarpine HCl Ophthalmic Solution
核心洞察
FDC Limited has received FDA approval for its abbreviated new drug application (ANDA) for pilocarpine hydrochloride ophthalmic solution in three concentrations (1%, 2%, and 4%).
The generic ophthalmic solution is indicated for multiple conditions including reduction of elevated intraocular pressure in glaucoma patients, management of acute angle-closure glaucoma (搜索), and induction of miosis for presbyopia (搜索).
This approval allows the India-based pharmaceutical company to market the generic version in the United States, potentially expanding access to this established glaucoma and presbyopia (搜索) treatment.
India-based pharmaceutical company FDC Limited has received FDA approval for its abbreviated new drug application (ANDA) for pilocarpine hydrochloride ophthalmic solution, marking the company's entry into the U.S. ophthalmic market with a generic version of this established eye medication.
The FDA approved three concentrations of the pilocarpine HCl solution: 1%, 2%, and 4%, each packaged in 15 mL containers. Unlike a standard new drug application (NDA), the ANDA approval pathway for generic drugs does not require preclinical and clinical data to establish safety and efficacy, but instead must demonstrate bioequivalence to the already FDA-approved reference product.
Multiple Therapeutic Applications
The approved pilocarpine HCl ophthalmic solution addresses several ophthalmic conditions with distinct dosing regimens for each indication. For reduction of elevated intraocular pressure in patients with open-angle glaucoma (搜索) or ocular hypertension (搜索), one drop of any concentration should be applied up to four times daily.
In acute angle-closure glaucoma (搜索) management, the dosing varies by clinical scenario. For initial management, one drop of 1% or 2% concentration may be applied up to three times over a 30-minute period. When laser procedures are involved, one drop of 4% concentration should be applied prior to laser iridoplasty or iridotomy, while 1% concentration is recommended four times daily following laser iridoplasty until iridotomy can be performed.
The solution also serves in preventing postoperative elevated intraocular pressure associated with laser surgery, requiring one or two drops (administered 5 minutes apart) applied 15 to 60 minutes prior to surgery. For presbyopia (搜索) treatment, one drop of any concentration, or two drops administered 5 minutes apart, should be applied to the affected eye(s).
Safety Profile and Precautions
The medication carries a major contraindication for patients with known hypersensitivity to pilocarpine. Key warnings include the risk of blurred vision, with patients advised not to drive or operate machinery if experiencing this side effect. Though rare, retinal detachment risk exists, and patients should seek immediate care if experiencing sudden onset of flashes, floaters, or vision loss.
Clinical trial data from the brand-name QLOSI (搜索) revealed that treatment-related adverse events occurred in 5-8% of patients, primarily instillation site pain and headaches. Ocular adverse events, particularly blurred vision, affected 2-5% of patients. Other reported reactions in ≥5% of patients using pilocarpine HCl for glaucoma or ocular hypertension (搜索) included eye irritation, visual impairment described as "dim, dark, or jumping vision," eye pain, and accommodative changes.
Market Context and Company Background
FDC Limited, originally founded in 1936 as Fairdeal Corporation, specializes in developing, manufacturing, and marketing both formulations and active pharmaceutical ingredients globally. The company's therapeutic portfolio spans ophthalmology, anti-infective, gastroenterology, dermatology, cardiovascular, and nutraceuticals sectors.
This approval enters a market where brand-name pilocarpine products have recently gained traction. Allergan, an AbbVie (搜索) company, received FDA approval for Vuity (pilocarpine HCl 1.25%) in 2021 and 2023 for once-daily and twice-daily formulations, respectively, both indicated for adult presbyopia (搜索). Additionally, Orasis Pharmaceuticals (搜索) launched QLOSI (搜索) (pilocarpine HCl 0.4%) earlier this year following its 2023 FDA approval for adult presbyopia treatment.
The availability and pricing details for FDC Limited's generic pilocarpine HCl ophthalmic solution remain to be determined, with the company expected to provide updates through its product site regarding market launch timing.